Use: Prophylaxis and treatment of venous thrombosis and PE. Usual Adult Dose for Pulmonary Embolism - Recurrent Event Usual Adult Dose for Pulmonary Embolism - First Event Usual Adult Dose for Deep Vein Thrombosis - Recurrent Event Usual Adult Dose for Deep Vein Thrombosis - First Event

Two episodes of unprovoked DVT or PE: Indefinite periodically reassess risk-benefit ratio of continuing such treatment.

Unprovoked DVT or PE: At least 3 months evaluate risk-benefit ratio of long-term treatment after 3 months.

Deep venous thrombosis (DVT) or pulmonary embolism (PE) secondary to a reversible risk factor: 3 months.

Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis Use: Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Usual Adult Dose for Myocardial Infarction - Prophylaxis Usual Adult Dose for Myocardial Infarctionĭuration of therapy: At least 3 months after myocardial infarction Use: Prophylaxis and treatment of thromboembolic complications associated with AF. Usual Adult Dose for Thromboembolic Stroke Prophylaxis Dosage and administration must be individualized according to the patient's INR and condition being treated.Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.

For patients with atrial fibrillation (AF) and prosthetic heart valves, target INR may be increased depending on valve type, valve position, and patient factors.Maintenance dose: 2 to 10 mg orally once a day Initial dose: 2 to 5 mg orally once a day Usual Adult Dose for Prevention of Thromboembolism in Atrial Fibrillation Prosthetic Heart Valves - Mechanical Valves.Prosthetic Heart Valves - Tissue Valves.Prevention of Thromboembolism in Atrial Fibrillation.

Inr antidote